title: Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
abstract: Histone deacetylase (HDAC) inhibitors (HDACis) are now attracting attention as promising therapeutic agents for the treatment of cancer. However, the relation between HDAC1 expression and the clinicopathological characteristics of non-small cell lung cancer (NSCLC) is not well understood. We therefore investigated the relationship between HDAC1 expression by tumors and the clinicopathological characteristics of patients with adenocarcinoma of the lung.
  
  
  METHODS
  We used semi-quantitative real time reverse transcription polymerase chain reaction to assess expression of HDAC1 mRNA in tumor samples from 93 patients with adenocarcinoma of the lung. We then correlated HDAC1 mRNA levels with known clinicopathological factors.
  
  
  RESULTS
  We found that the 5-year disease-free survival rate among patients strongly expressing HDAC1 was significantly poorer than among those expressing lower levels (P=0.005 by log-rank test). Multivariate Cox proportional hazard analyses revealed that being male (hazard ratio, 3.56; 95% CI, 1.58-8.42; P=0.002), nodal metastasis (hazard ratio, 7.98; 95% CI, 2.99-22.1; P<.001) and HDAC1 (hazard ratio, 2.17; 95% CI, 1.04-4.84; P=0.039) were all independent factors affecting 5-year disease-free survival.
  
  
  CONCLUSIONS
  Stronger HDAC1 expression by tumor cells is an independent predictor of a poor prognosis in patients with adenocarcinoma of the lung.
authors.affiliation: The Division of Thoracic Surgery, Breast and Endocrine Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita City 010-8543, Japan. minamiya@med.akita-u.ac.jp
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Minamiya
authors.forename: Takashi
authors.initials: T
authors.lastname: Ono
authors.forename: Hajime
authors.initials: H
authors.lastname: Saito
authors.forename: Naoko
authors.initials: N
authors.lastname: Takahashi
authors.forename: Manabu
authors.initials: M
authors.lastname: Ito
authors.forename: Masafumi
authors.initials: M
authors.lastname: Mitsui
authors.forename: Satoru
authors.initials: S
authors.lastname: Motoyama
authors.forename: Junichi
authors.initials: J
authors.lastname: Ogawa
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D056284:Histone Deacetylase 1 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D012737:Sex Factors; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D056284:Histone Deacetylase 1